Cancer care continues to evolve with the introduction of targeted therapies that improve treatment precision and expand options for patients with advanced disease. Regorafenib 40mg Tablets have emerged as an important oral targeted therapy for specific difficult-to-treat cancers, offering healthcare providers additional therapeutic strategies when previous treatments are no longer effective.
As global demand for affordable oncology medicines rises, India has also strengthened its role as a trusted source for high-quality anti-cancer medicines and pharmaceutical exports.
What Are Regorafenib 40mg Tablets?
Regorafenib is an oral multi-kinase inhibitor used in oncology treatment protocols for advanced cancers. It works by targeting multiple pathways involved in tumor growth, angiogenesis, and cancer progression. By blocking proteins associated with tumor development and blood vessel formation, regorafenib helps slow disease progression in selected patient populations.
The medicine is commonly available in 40mg tablet strength and is administered under specialist supervision as part of individualized oncology treatment plans.
Cancer Treatment Applications of Regorafenib 40mg Tablets
Regorafenib is widely recognized in modern oncology for its role in treating multiple advanced cancers.
Metastatic Colorectal Cancer (mCRC)
Regorafenib is indicated for patients with metastatic colorectal cancer who have progressed following standard chemotherapy and targeted treatment options. This makes it an important component in late-line colorectal cancer management.
Gastrointestinal Stromal Tumors (GIST)
Patients with unresectable or metastatic GIST who have previously received earlier-line therapies may benefit from regorafenib therapy as part of continued disease management.
Hepatocellular Carcinoma (HCC)
Regorafenib is also used in selected patients with advanced liver cancer after prior systemic treatment exposure. Its inclusion in treatment pathways provides additional options for oncologists managing progressive disease.
Patient Benefits of Regorafenib 40mg Tablets
Oral Targeted Therapy Convenience
As an oral anti-cancer medication, regorafenib provides greater convenience compared to infusion-based treatments, potentially reducing hospital visits and improving treatment flexibility.
Precision-Based Mechanism
The targeted mechanism focuses on signaling pathways associated with cancer progression rather than generalized cytotoxic activity, supporting modern precision oncology approaches.
Additional Treatment Opportunities
For patients with limited remaining treatment choices, regorafenib offers another line of therapy that can support ongoing disease management strategies.
Broad Oncology Relevance
Its application across colorectal cancer, liver cancer, and GIST makes regorafenib a versatile molecule within oncology portfolios.
Dosage Administration and Usage Guidelines
Regorafenib therapy should only be prescribed and monitored by experienced oncology specialists.
Standard dosing guidance includes:
Recommended dosage: 160 mg orally once daily (four 40mg tablets)
Treatment schedule: Daily administration for 21 days followed by a 7-day break within a 28-day treatment cycle
Tablets should be swallowed whole with water
Administration is generally recommended after a low-fat meal and at approximately the same time each day
Dose adjustments may be required depending on tolerability and adverse reactions management.
Safety Monitoring Considerations
Healthcare professionals generally monitor patients for:
Liver function abnormalities
Hypertension
Hand-foot skin reactions
Fatigue
Gastrointestinal adverse effects
Bleeding-related complications
Regular clinical assessments remain important throughout therapy.
Export Availability of Regorafenib 40mg Tablets from India
India has become a leading global supplier of oncology medicines due to its large-scale manufacturing infrastructure, regulatory expertise, and cost-effective production ecosystem.
Growing international demand for affordable cancer medicines has strengthened India’s pharmaceutical export capabilities, with exports exceeding $30 billion in recent years.
Why Source Regorafenib 40mg Tablets from India?
WHO-GMP compliant manufacturing facilities
Cost-efficient oncology medicine production
Large-volume supply capabilities
Support for regulated and semi-regulated markets
Regulatory documentation support
Global logistics and distribution infrastructure
Indian exporters increasingly provide customized packaging, dossier support, and supply chain management services for hospitals, distributors, procurement agencies, and government healthcare programs. WHO-GMP-certified manufacturers and exporters continue expanding access to oncology medicines worldwide.
Future Outlook for Oncology Medicine Supply
Global demand for targeted cancer therapies continues to increase, reinforcing the importance of reliable pharmaceutical manufacturing and export net
As global demand for affordable oncology medicines rises, India has also strengthened its role as a trusted source for high-quality anti-cancer medicines and pharmaceutical exports.
What Are Regorafenib 40mg Tablets?
Regorafenib is an oral multi-kinase inhibitor used in oncology treatment protocols for advanced cancers. It works by targeting multiple pathways involved in tumor growth, angiogenesis, and cancer progression. By blocking proteins associated with tumor development and blood vessel formation, regorafenib helps slow disease progression in selected patient populations.
The medicine is commonly available in 40mg tablet strength and is administered under specialist supervision as part of individualized oncology treatment plans.
Cancer Treatment Applications of Regorafenib 40mg Tablets
Regorafenib is widely recognized in modern oncology for its role in treating multiple advanced cancers.
Metastatic Colorectal Cancer (mCRC)
Regorafenib is indicated for patients with metastatic colorectal cancer who have progressed following standard chemotherapy and targeted treatment options. This makes it an important component in late-line colorectal cancer management.
Gastrointestinal Stromal Tumors (GIST)
Patients with unresectable or metastatic GIST who have previously received earlier-line therapies may benefit from regorafenib therapy as part of continued disease management.
Hepatocellular Carcinoma (HCC)
Regorafenib is also used in selected patients with advanced liver cancer after prior systemic treatment exposure. Its inclusion in treatment pathways provides additional options for oncologists managing progressive disease.
Patient Benefits of Regorafenib 40mg Tablets
Oral Targeted Therapy Convenience
As an oral anti-cancer medication, regorafenib provides greater convenience compared to infusion-based treatments, potentially reducing hospital visits and improving treatment flexibility.
Precision-Based Mechanism
The targeted mechanism focuses on signaling pathways associated with cancer progression rather than generalized cytotoxic activity, supporting modern precision oncology approaches.
Additional Treatment Opportunities
For patients with limited remaining treatment choices, regorafenib offers another line of therapy that can support ongoing disease management strategies.
Broad Oncology Relevance
Its application across colorectal cancer, liver cancer, and GIST makes regorafenib a versatile molecule within oncology portfolios.
Dosage Administration and Usage Guidelines
Regorafenib therapy should only be prescribed and monitored by experienced oncology specialists.
Standard dosing guidance includes:
Recommended dosage: 160 mg orally once daily (four 40mg tablets)
Treatment schedule: Daily administration for 21 days followed by a 7-day break within a 28-day treatment cycle
Tablets should be swallowed whole with water
Administration is generally recommended after a low-fat meal and at approximately the same time each day
Dose adjustments may be required depending on tolerability and adverse reactions management.
Safety Monitoring Considerations
Healthcare professionals generally monitor patients for:
Liver function abnormalities
Hypertension
Hand-foot skin reactions
Fatigue
Gastrointestinal adverse effects
Bleeding-related complications
Regular clinical assessments remain important throughout therapy.
Export Availability of Regorafenib 40mg Tablets from India
India has become a leading global supplier of oncology medicines due to its large-scale manufacturing infrastructure, regulatory expertise, and cost-effective production ecosystem.
Growing international demand for affordable cancer medicines has strengthened India’s pharmaceutical export capabilities, with exports exceeding $30 billion in recent years.
Why Source Regorafenib 40mg Tablets from India?
WHO-GMP compliant manufacturing facilities
Cost-efficient oncology medicine production
Large-volume supply capabilities
Support for regulated and semi-regulated markets
Regulatory documentation support
Global logistics and distribution infrastructure
Indian exporters increasingly provide customized packaging, dossier support, and supply chain management services for hospitals, distributors, procurement agencies, and government healthcare programs. WHO-GMP-certified manufacturers and exporters continue expanding access to oncology medicines worldwide.
Future Outlook for Oncology Medicine Supply
Global demand for targeted cancer therapies continues to increase, reinforcing the importance of reliable pharmaceutical manufacturing and export net
Keywords
